Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about using Biolabshop's RU58841 product, which includes GHK-Cu and melatonin, to improve hair quality and combat hair loss. The user has previously used finasteride, minoxidil, and Anageninc’s RU58841 with success and seeks feedback on the new product, especially from those on anabolic steroids or hormone treatments.

The conversation is about someone planning to start finasteride for hair loss and wanting to interpret pre-treatment blood panels to assess the risk of side effects like gynecomastia. They list various tests to measure hormone levels and other health indicators.

David Barreto shared that a London-based research group is conducting a 12-month trial for a new nutraceutical treatment for pattern hair loss, designed with Dr. Carlos Puig. The trial aims to provide robust data, with results expected in 1-2 years, potentially representing a significant advancement since finasteride’s introduction in 1997.

JXL082 is not the same as PP405, leading to a halt in sales and a plan to synthesize the real PP405. There is skepticism about the safety and effectiveness of JXL082 and PP405, with concerns about patent issues and the long-term impact on hair growth.

A user's regimen to help with their diffuse thinning, which includes taking Pyrilutamide BID, 1mg finasteride daily, 2.5mg oral minoxidil daily, topical minoxidil since August 2021, LLLT every two days, topical fin, progesterone, melatonin, minoxidil (started one week ago), pumpkin seed oil and not dermarolling; other commenters suggested Nizoral for dandruff control and caution when using pre-mixed products with Pyrilutamide.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

Switching from finasteride to dutasteride can lead to varied results, with some experiencing better hair regrowth and fewer side effects, while others continue to lose hair. Dutasteride is generally seen as more effective but has a longer half-life, potentially extending side effects.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

Fluridil's effectiveness and safety in treating hair loss are discussed, with higher concentrations showing potential success. Comparisons are made to other treatments like RU58841, Pyri, CB-03-01, and topical spironalactone.

The user noticed slight hair loss after switching to Milpharm finasteride and is considering switching to Accord finasteride. They seek advice on whether to continue with Milpharm or switch brands.

Breezula offers modest hair growth similar to finasteride and is expected to be available by late 2026. It is a safe alternative without hormonal side effects and works well with minoxidil.

A user's extreme regimen for hair loss, which includes taking oral and topical medications such as minoxidil, dutasteride, cyproterone acetate and bicalutamide, but still experiencing miniaturization. Suggestions were made to try other treatments such as RU58841 and Pyrilutamide, while also considering mental health treatment and advice on lookmaxxing.

A user is concerned about a change in the formula of Sons topical treatment, which now requires fewer sprays but contains less minoxidil. They question if the change is for convenience or if it's a way to charge the same for less product.

The conversation discusses the effectiveness of different concentrations and dosages of topical finasteride on scalp and serum DHT levels, comparing it to oral finasteride and noting the side effects seem to be fewer at lower dosages. Participants shared experiences and referenced a chart indicating similar scalp DHT reduction with 0.025% topical finasteride as with 1mg oral finasteride, but with fewer side effects.

A 26-year-old male shares his progress using 0.5mg finasteride and 5% topical minoxidil for hair loss, considering transitioning to 3mg oral minoxidil. He is also contemplating using a hair system to boost confidence while continuing treatment.

The user experienced no improvement in hair loss with finasteride and minoxidil but had side effects. They plan to add wounding, scalp massage, vitamin K, and taurine supplements to their regimen and seek feedback on these additions.

Dutasteride raises scalp testosterone by 99%, which may not be ideal for those sensitive to all androgens. Some argue finasteride's balancing act might be better, while others believe dutasteride is superior for hair regrowth.

Finasteride can affect hormone levels within two weeks, and a break of several weeks is recommended for baseline results. Monitoring E2 and testosterone is suggested to assess the risk of gynecomastia.

A user shared their positive experience with a 4-in-1 topical solution containing finasteride, minoxidil, ketoconazole, and biotin, along with weekly microneedling using a 1.2mm dermastamp. The user reported no noticeable side effects and mentioned that the biotin likely doesn't contribute to hair growth.

TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.

The user follows an intensive hair loss protocol including dutasteride, biotin, black tea, pumpkin seed oil, peppermint shampoo, rosemary conditioner, mukemame, soy milk, lycopene, garlic, magnesium, chamomile, spicy food, citrus bergamot, zinc, multivitamins, kefir, and Greek yogurt. They plan to alternate between pumpkin seed oil and safflower oil and will share before and after pictures.

The conversation is about someone seeking a doctor in the EU who prescribes spironolactone or bicalutamide for female pattern hair loss, as they are having difficulty finding treatment options beyond Minoxidil in Austria. They are asking for recommendations and are open to direct messages for assistance.

Hair loss treatment with latanoprost, minoxidil, and biotin showed progress. Latanoprost, a glaucoma drug, stimulates anagen phase and increases conversion of vellus hair to terminal hair.

The user, EggplantAncient7506, is asking if there is an improvement in their general hair quality after using Finasteride since December 22. Replies suggest that there is an improvement.

User shares 6.5 months of progress using topical finasteride 0.1% and minoxidil 10%, along with lasercomb, dermaroller, Nizoral, scalp massager, and biotin. They seek feedback on their results.

The conversation is about comparing hair loss treatments Pyrilutamide (KX-826) and CB-03-01, discussing their cost, side effects, and effectiveness. The user questions whether to try CB-03-01, which is more expensive and potentially less effective, or switch to the cheaper and possibly better Pyrilutamide.

PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.

A 30-year-old male switched from finasteride to a combination of dutasteride, oral minoxidil, and RU58841, achieving significant hair growth without side effects. He plans to add GHK-Cu peptide to his regimen for further improvement.

PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.